Shields Health Solutions

shieldshealthsolutions.com

One of the fastest growing companies in America, Shields Health Solutions partners with hospital leaders on every aspect of specialty pharmacy creation and growth. The company provides the fastest, lowest risk model for Hospital leaders to create and grow a hospital-owned specialty pharmacy business, whether starting from scratch or adding specialty capabilities to a hospital’s existing pharmacy programs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AI

IKTOS PARTNERS WITH KADMON TO USE AI FOR NEW DRUG DESIGN

Iktos, Kadmon | May 19, 2021

news image

Iktos, a company specializing in Artificial Intelligence for new drug design, announced today that it has signed a Research Collaboration Agreement with Kadmon, a clinical-stage biopharmaceutical company based in New York, USA, under which Iktos' generative modeling artificial intelligence (AI) technology will be used to allow the rapid and cost-effective design of novel drug candidates. Iktos will use its de novo structure-based generative modeling technologies to find novel compounds that ...

Read More

Medical

FRESH FROM RAISING $200M, BRITISH BIOTECH WITH AN HQ IN RALEIGH MULLS TARGETING COVID-19

Verona Pharma | November 19, 2020

news image

A British clinical-stage biotech firm with U.S. base camp in Raleigh is investigating the alternative of repurposing its leading drug candidate to treat COVID-19 patients. Flush with $200 million after a July raise, the London-based Verona Pharma is now making large walks with its "first-in-class" drug, ensifentrine, targeting chronic obstructive pulmonary disease (COPD). Now, against the backdrop of a pandemic, it’s pushing ahead with a pilot clinic...

Read More

MedTech, Industrial Impact

GENERATE BIOMEDICINES EXPANDS LEADERSHIP TEAM WITH CHIEF DIGITAL OFFICER

Generate Biomedicines | December 07, 2022

news image

Generate Biomedicines announced that Dimitris Agrafiotis, Ph.D., FRSC, has been appointed Chief Digital Officer. He will lead multidisciplinary teams across technology, data science, automation, and digital transformation to support the rapid growth of the machine learning-powered biotech. Dr. Agrafiotis brings deep expertise at the intersection of digital technology, data science, and life sciences spanning the entire R&D continuum across venture-funded biotech, big pharma, a...

Read More

Research

PHARMABCINE TO PRESENT UPDATED INTERIM DATA FROM THE ONGOING PHASE IB TRIAL OF OLINVACIMAB AND PEMBROLIZUMAB COMBINATION THERAPY

PharmAbcine | December 08, 2020

news image

PharmAbcine Inc., a clinical-stage biotech organization focusing in on the improvement of completely human antibody therapeutics, declared today that the organization will introduce the refreshed break information from the continuous stage Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020) occurring for all intents and purposes over December 8-11, 2020.
Read More

news image

AI

IKTOS PARTNERS WITH KADMON TO USE AI FOR NEW DRUG DESIGN

Iktos, Kadmon | May 19, 2021

Iktos, a company specializing in Artificial Intelligence for new drug design, announced today that it has signed a Research Collaboration Agreement with Kadmon, a clinical-stage biopharmaceutical company based in New York, USA, under which Iktos' generative modeling artificial intelligence (AI) technology will be used to allow the rapid and cost-effective design of novel drug candidates. Iktos will use its de novo structure-based generative modeling technologies to find novel compounds that ...

Read More
news image

Medical

FRESH FROM RAISING $200M, BRITISH BIOTECH WITH AN HQ IN RALEIGH MULLS TARGETING COVID-19

Verona Pharma | November 19, 2020

A British clinical-stage biotech firm with U.S. base camp in Raleigh is investigating the alternative of repurposing its leading drug candidate to treat COVID-19 patients. Flush with $200 million after a July raise, the London-based Verona Pharma is now making large walks with its "first-in-class" drug, ensifentrine, targeting chronic obstructive pulmonary disease (COPD). Now, against the backdrop of a pandemic, it’s pushing ahead with a pilot clinic...

Read More
news image

MedTech, Industrial Impact

GENERATE BIOMEDICINES EXPANDS LEADERSHIP TEAM WITH CHIEF DIGITAL OFFICER

Generate Biomedicines | December 07, 2022

Generate Biomedicines announced that Dimitris Agrafiotis, Ph.D., FRSC, has been appointed Chief Digital Officer. He will lead multidisciplinary teams across technology, data science, automation, and digital transformation to support the rapid growth of the machine learning-powered biotech. Dr. Agrafiotis brings deep expertise at the intersection of digital technology, data science, and life sciences spanning the entire R&D continuum across venture-funded biotech, big pharma, a...

Read More
news image

Research

PHARMABCINE TO PRESENT UPDATED INTERIM DATA FROM THE ONGOING PHASE IB TRIAL OF OLINVACIMAB AND PEMBROLIZUMAB COMBINATION THERAPY

PharmAbcine | December 08, 2020

PharmAbcine Inc., a clinical-stage biotech organization focusing in on the improvement of completely human antibody therapeutics, declared today that the organization will introduce the refreshed break information from the continuous stage Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020) occurring for all intents and purposes over December 8-11, 2020.
Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us